H.-J. Lück

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system

Edgar Petru, H.-J. Lück, Gavin Stuart et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 2009 · 82 citations

Medicine, Gynecology, Oncology +12

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors

Isabelle Ray‐Coquard, Philipp Harter, Domenica Lorusso et al. · JAMA Oncology · 2020 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase I study of weekly docetaxel (Taxotere®) in heavily pretreated breast cancer patients

H.-J. Lück, S. Donnè, Michael Glaubitz et al. · European Journal of Cancer · 1997 · 30 citations

Medicine, Oncology, Pharmacology +14

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

Roberto Sorio, C. Roemer-Bécuwe, Felix Hilpert et al. · Gynecologic Oncology · 2016 · 27 citations

Medicine, Oncology, Pharmacotherapy +14